Pentixapharm Holding AG Logo

Pentixapharm Holding AG

Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.

PTP | F

Overview

Corporate Details

ISIN(s):
DE000A383RV0 (+1 more)
LEI:
3912005VBOVXNDXEQZ36
Country:
Germany
Address:
Robert-Rössle-Straße, 10, 13125 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical development company that creates innovative, first-in-class compounds for both diagnostic and therapeutic applications. The company's pipeline primarily targets unmet medical needs in oncology, including hemato-oncology and solid tumors, as well as adrenal disorders. Key assets include two Phase III-ready drug candidates and a well-researched CXCR4-targeting compound. With a strong research and development focus, Pentixapharm has administered its compounds to over 2,000 patients in clinical settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 11:00
Regulatory News Service
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New …
English 10.5 KB
2025-09-26 08:00
Regulatory News Service
Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acut…
English 11.3 KB
2025-09-16 15:19
Director's Dealing
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.1 KB
2025-09-15 11:49
Director's Dealing
Pentixapharm Holding AG: Dr. Andreas Eckert, buy
English 5.8 KB
2025-08-06 00:00
Interim Report
Half-yearly financial report 2025
English 723.4 KB
2025-07-24 14:04
Report Publication Announcement
English 3.9 KB
2025-05-27 09:43
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
English 10.0 KB
2025-05-08 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 479.2 KB
2025-04-26 16:00
Report Publication Announcement
English 3.8 KB
2025-04-25 00:00
Annual Report
Annual financial report 2024
English 2.3 MB
2025-04-24 14:00
Regulatory News Service
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based Pentix…
English 8.8 KB
2025-04-17 15:05
Pre-Annual General Meeting Information
Pentixapharm Holding AG: Bekanntmachung der Einberufung zur Hauptversammlung am…
German 88.5 KB
2025-04-15 08:17
Report Publication Announcement
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guida…
English 6.4 KB
2025-03-19 13:20
Report Publication Announcement
English 3.9 KB
2025-03-18 13:20
Report Publication Announcement
English 3.9 KB

Automate Your Workflow. Get a real-time feed of all Pentixapharm Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pentixapharm Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pentixapharm Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden ORX
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland ORNAV
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea 475830
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany PA8
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea 222110
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea 304840

Talk to a Data Expert

Have a question? We'll get back to you promptly.